# pleural mesothelioma stages

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial » Nivolumab represents a treatment that might be beneficial to patients with malignant mesothelioma who have progressed on first-line therapy. Thelancet.com

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study » OncoCast-MPM generated accurate, individual patient-level risk assessment scores. After prospective validation with the TCGA cohort, OncoCast-MPM might offer new opportunities for enhanced risk stratification of patients with malignant pleural mesothelioma in clinical trials and drug development. Thelancet.com

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ » Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in exposures with world-standardised incidence rates per 100 000 persons of 0.7 and 0.3 in the United States and 1.7 and 0.4 for Europe (for males and females, respectively). Incidence is highest in countries with greatest previous asbestos use such as the Netherlands, UK and Australia.1 Due to a lag time of ∼40 years between exposure and presentation, alongside relatively recent usage bans, incidence continues to rise in many countries. Annalsofoncology.org

Appendix C: Site Specific Coding Modules - 2022 SEER Coding and Staging Manual » 2022 SEER Coding and Staging Manual. << Historical Staging and Coding Manuals… Pleural Mesothelioma (PDF, 233 KB). EOD Schemas. Heart, Mediastinum and Pleura … Seer.cancer.gov

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma » Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known… Ncbi.nlm.nih.gov